NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM NEWEST
2025/2026 WITH COMPLETE 200 QUESTIONS AND CORRECT
ANSWERS |ALREADY GRADED A+||BRAND NEW VERSION!
In caring for a patient receiving therapy with a myelosuppressive antineoplastic
drug, the nurse notes an order to begin filgrastim after the chemotherapy is
completed. Which statement correctly describes when the nurse will begin the
filgrastim therapy?
A. It can be started during the chemotherapy.
B. It will begin immediately after the chemotherapy is completed.
C. It will be started 24 hours after the chemotherapy is completed.
D. It will not be started until at least 72 hours after the chemotherapy is
completed.
C. It will be started 24 hours after the chemotherapy is completed.
The nurse is monitoring a patient who has been receiving aldesleukin (IL-2) for
treatment of malignant melanoma. Which adverse effect, if noted on assessment,
is of primary concern?
A. Diarrhea.
B. Fatigue.
C. Nausea.
D. Fluid retention.
D. Fluid retention.
The nurse is reviewing the medical history of a patient who is about to receive
therapy with etanercept. Which conditions, if present, would be a
contraindication or caution for therapy with this drug? Select all that apply.
A. Urinary tract infection.
B. Psoriasis.
1|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
C. Heart failure.
D. Glaucoma.
E. Latex allergy.
A. Urinary tract infection.
C. Heart failure.
E. Latex allergy.
The nurse notes in the patient's medication history that the patient is taking
natalizumab. Based on this finding, the nurse interprets that the patient has which
disorder?
A. Multiple sclerosis.
B. Rheumatoid arthritis.
C. Non-Hodgkin lymphoma.
D. Crohn's disease.
A. Multiple sclerosis.
A patient has a new order for glatiramer acetate. The patient has not had an organ
transplant. The nurse knows that the patient is receiving this drug for which
condition?
A. Psoriasis.
B. Rheumatoid arthritis.
C. Irritable bowel syndrome.
D. Relapse-remitting multiple sclerosis.
D. Relapse-remitting multiple sclerosis.
The nurse is preparing to administer sirolimus and is aware that this drug has a
black box warning for which possible condition?
A. Heart failure.
B. Lymphoma.
2|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
C. Severe hypertension.
D. Cytokine release syndrome.
B. Lymphoma.
During therapy with azathioprine, the nurse must monitor for which adverse
effects? Select all that apply.
A. Liver toxicity.
B. Diarrhea.
C. Vomiting.
D. Bradycardia.
E. Thrombocytopenia.
A. Liver toxicity.
E. Thrombocytopenia.
During a teaching session for a patient receiving an immunosuppressant drug, the
nurse will include which statement?
A. "It is better to use oral forms of these drugs to prevent the occurrence of
thrush."
B. "You will remain on antibiotics to prevent infection."
C. "It is important to use some form of contraception during treatment and for up
to 12 weeks after the end of therapy."
D. "Be sure to take your medications with grapefruit juice to increase absorption."
C. "It is important to use some form of contraception during treatment and for up
to 12 weeks after the end of therapy."
During drug therapy with basiliximab, the nurse monitors for signs of cytokine
release syndrome, which results in which of these?
A. Fever, dyspnea, and general malaise.
3|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
B. Neurotoxicity and peripheral neuropathy.
C. Hepatotoxicity with jaundice.
D. Thrombocytopenia with increased bleeding tendencies.
A. Fever, dyspnea, and general malaise.
When assessing a patient who is to begin therapy with an immunosuppressant
drug, the nurse recognizes that such drugs should be used cautiously in patients
with which condition(s)? Select all that apply.
A. Pregnancy.
B. Glaucoma.
C. Anemia.
D. Myalgia.
E. Renal failure.
F. Liver failure.
A. Pregnancy.
E. Renal failure.
F. Liver failure
The nurse is reviewing cyclosporine and recognizes that this drug works by which
mechanism of action?
A. Suppressing viral replication.
B. Enhancing the action of macrophages.
C. Inhibiting activation of T-lymphocyte cells.
D. Increasing the number of T-lymphocyte cells.
C. Inhibiting activation of T-lymphocyte cells.
4|Page
NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM NEWEST
2025/2026 WITH COMPLETE 200 QUESTIONS AND CORRECT
ANSWERS |ALREADY GRADED A+||BRAND NEW VERSION!
In caring for a patient receiving therapy with a myelosuppressive antineoplastic
drug, the nurse notes an order to begin filgrastim after the chemotherapy is
completed. Which statement correctly describes when the nurse will begin the
filgrastim therapy?
A. It can be started during the chemotherapy.
B. It will begin immediately after the chemotherapy is completed.
C. It will be started 24 hours after the chemotherapy is completed.
D. It will not be started until at least 72 hours after the chemotherapy is
completed.
C. It will be started 24 hours after the chemotherapy is completed.
The nurse is monitoring a patient who has been receiving aldesleukin (IL-2) for
treatment of malignant melanoma. Which adverse effect, if noted on assessment,
is of primary concern?
A. Diarrhea.
B. Fatigue.
C. Nausea.
D. Fluid retention.
D. Fluid retention.
The nurse is reviewing the medical history of a patient who is about to receive
therapy with etanercept. Which conditions, if present, would be a
contraindication or caution for therapy with this drug? Select all that apply.
A. Urinary tract infection.
B. Psoriasis.
1|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
C. Heart failure.
D. Glaucoma.
E. Latex allergy.
A. Urinary tract infection.
C. Heart failure.
E. Latex allergy.
The nurse notes in the patient's medication history that the patient is taking
natalizumab. Based on this finding, the nurse interprets that the patient has which
disorder?
A. Multiple sclerosis.
B. Rheumatoid arthritis.
C. Non-Hodgkin lymphoma.
D. Crohn's disease.
A. Multiple sclerosis.
A patient has a new order for glatiramer acetate. The patient has not had an organ
transplant. The nurse knows that the patient is receiving this drug for which
condition?
A. Psoriasis.
B. Rheumatoid arthritis.
C. Irritable bowel syndrome.
D. Relapse-remitting multiple sclerosis.
D. Relapse-remitting multiple sclerosis.
The nurse is preparing to administer sirolimus and is aware that this drug has a
black box warning for which possible condition?
A. Heart failure.
B. Lymphoma.
2|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
C. Severe hypertension.
D. Cytokine release syndrome.
B. Lymphoma.
During therapy with azathioprine, the nurse must monitor for which adverse
effects? Select all that apply.
A. Liver toxicity.
B. Diarrhea.
C. Vomiting.
D. Bradycardia.
E. Thrombocytopenia.
A. Liver toxicity.
E. Thrombocytopenia.
During a teaching session for a patient receiving an immunosuppressant drug, the
nurse will include which statement?
A. "It is better to use oral forms of these drugs to prevent the occurrence of
thrush."
B. "You will remain on antibiotics to prevent infection."
C. "It is important to use some form of contraception during treatment and for up
to 12 weeks after the end of therapy."
D. "Be sure to take your medications with grapefruit juice to increase absorption."
C. "It is important to use some form of contraception during treatment and for up
to 12 weeks after the end of therapy."
During drug therapy with basiliximab, the nurse monitors for signs of cytokine
release syndrome, which results in which of these?
A. Fever, dyspnea, and general malaise.
3|Page
, NSG367 EXAM 3 / NSG367 EXAM 3 ACTUAL EXAM
B. Neurotoxicity and peripheral neuropathy.
C. Hepatotoxicity with jaundice.
D. Thrombocytopenia with increased bleeding tendencies.
A. Fever, dyspnea, and general malaise.
When assessing a patient who is to begin therapy with an immunosuppressant
drug, the nurse recognizes that such drugs should be used cautiously in patients
with which condition(s)? Select all that apply.
A. Pregnancy.
B. Glaucoma.
C. Anemia.
D. Myalgia.
E. Renal failure.
F. Liver failure.
A. Pregnancy.
E. Renal failure.
F. Liver failure
The nurse is reviewing cyclosporine and recognizes that this drug works by which
mechanism of action?
A. Suppressing viral replication.
B. Enhancing the action of macrophages.
C. Inhibiting activation of T-lymphocyte cells.
D. Increasing the number of T-lymphocyte cells.
C. Inhibiting activation of T-lymphocyte cells.
4|Page
